RxDoctor Payments DataLook up a doctor →

Lawrence Seiden, MD

Neurology · Atlanta, GANPI 1295709772

Payments from drug & device makers

$280,506in general payments, 2019–2025

Across 808 payments — averaging $347.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$163K
  • UCB, Inc.$59K
  • Jazz Pharmaceuticals Inc.$29K
  • Greenwich Biosciences, Inc.$14K
  • Sunovion Pharmaceuticals Inc.$8K
  • EMD Serono, Inc.$938
  • plus $7K from 52 others

What the payments were for

  • Consulting fees$57,66021%
  • Speaking & faculty fees$177,99365%
  • Travel & lodging$17,0436%
  • Food & beverage$19,6417%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.177$163,250
UCB, Inc.170$58,633
Jazz Pharmaceuticals Inc.44$28,928
Greenwich Biosciences, Inc.30$13,810
Sunovion Pharmaceuticals Inc.15$8,439
EMD Serono, Inc.67$938
Livanova USA, Inc.11$821
Novartis45$596
Biogen28$525
AbbVie25$497
Acadia Pharmaceuticals Inc27$366
Teva Pharmaceuticals USA, Inc.17$306
Neurocrine Biosciences, Inc.12$274
Eisai Inc.8$270
Amgen(2 entities)13$262
Lundbeck LLC10$260
Pfizer11$221
Neurelis, Inc.7$150
Banner Life Sciences, LLC7$136
Argenx US, Inc.6$131
AstraZeneca(2 entities)5$123
Vanda Pharmaceuticals Inc.4$113
Mallinckrodt Hospital Products Inc.5$104
TG Therapeutics, Inc.4$95
Otsuka America Pharmaceutical, Inc.4$93
Sanofi3$87
Boston Scientific1$83
Lilly USA, LLC5$81
Amneal Pharmaceuticals LLC5$73
Merz Pharmaceuticals, LLC3$72
ANI Pharmaceuticals, Inc.3$67
Harmony Biosciences LLC3$61
Impel Pharmaceuticals Inc.3$58
Catalyst Pharmaceuticals, Inc.2$48
Cycle Pharmaceuticals Inc2$43
Aucta Pharmaceuticals, Inc.3$43
MDD US Operations, LLC1$36
Kyowa Kirin, Inc.2$30
Invivyd Inc1$27
Bristol Myers Squibb1$27
Bausch Health US, LLC1$25
Acorda Therapeutics, Inc1$24
Upsher-smith Laboratories LLC1$22
Kedrion Biopharma, Inc.1$22
Alnylam Pharmaceuticals Inc.1$21
Akcea Therapeutics, Inc.1$21
Axsome Therapeutics, Inc.1$20
Immedica Pharma US, Inc.1$20
Idorsia Pharmaceuticals US Inc1$19
Octapharma USA, Inc.1$18
Supernus Pharmaceuticals, Inc.1$18
Zyla Life Sciences, Inc.1$18
Biohaven Pharmaceuticals, Inc.1$18
Vertical Pharmaceuticals, LLC1$17
Tanabe Pharma America, Inc.1$16
Avanir Pharmaceuticals, Inc.1$15
Adamas Pharmaceuticals, Inc.1$13
Impel Pharmaceuticals LLC1$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$280,506 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$121,103
Medicare patients
328
Services billed
1,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate285$502,993
EpidiolexCannabidiol (Cbd)36$157,013
BriviactBrivaracetam51$87,509
Lamictal XrLamotrigine17$84,699
KeppraLevetiracetam15$63,100
VimpatLacosamide45$51,323
Keppra XrLevetiracetam33$46,240
NayzilamMidazolam32$37,277
FelbatolFelbamate12$34,209
Lacosamide177$33,094
Levetiracetam391$23,430
Nurtec OdtRimegepant Sulfate13$22,418
AptiomEslicarbazepine Acetate13$16,642
Clobazam73$12,330
Lamotrigine ErLamotrigine36$12,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$163,250$502,993285 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$58,633$176,109128 claims
PfizerNurtec Odt, Dilantin$221$28,54527 claims
Sunovion Pharmaceuticals Inc.Aptiom$8,439$16,64213 claims
Upsher-smith Laboratories LLCTopiramate$22$88262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →